Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maxacalcitol - Chugai Pharmaceutical

Drug Profile

Maxacalcitol - Chugai Pharmaceutical

Alternative Names: 22-oxacalcitriol; OCT; Oxarol

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Maruho
  • Class Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ichthyosis; Palmoplantar keratoderma; Palmoplantar pustulosis; Psoriasis; Secondary hyperparathyroidism

Most Recent Events

  • 01 Dec 2019 Chugai Pharmaceutical completes transfer of rights for maxacalcitol to Maruho in Japan
  • 30 Jan 2019 Chugai Pharmaceutical plans to transfer rights for Maxacalcitol to Maruho from December 1, 2019
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Secondary-hyperparathyroidism(In volunteers) in Taiwan (IV, Injection)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top